TSXV - Delayed Quote CAD
Waverley Pharma Inc. (WAVE.V)
0.0100
0.0000
(0.00%)
At close: April 23 at 11:52:38 AM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
338.4210
412.0900
1,246.8320
1,752.8480
1,375.1050
Cost of Revenue
268.6800
332.2890
963.0430
1,530.1790
1,193.3990
Gross Profit
69.7410
79.8010
283.7890
222.6690
181.7060
Operating Expense
1,251.1720
1,313.6850
921.9450
1,009.4950
891.3070
Operating Income
-1,181.4310
-1,233.8840
-638.1560
-786.8260
-709.6010
Net Non Operating Interest Income Expense
-98.0210
-76.6530
-16.6380
-3.0370
5.3920
Other Income Expense
-907.5460
-913.5110
-9.2820
-6.6440
-1.5540
Pretax Income
-2,186.9980
-2,224.0480
-664.0760
-796.5070
-705.7630
Net Income Common Stockholders
-2,186.9980
-2,224.0480
-664.0760
-796.5070
-705.7630
Diluted NI Available to Com Stockholders
-2,186.9980
-2,224.0480
-664.0760
-796.5070
-705.7630
Basic EPS
-0.04
-0.04
-0.01
-0.01
-0.01
Diluted EPS
-0.04
-0.04
-0.01
-0.01
-0.01
Basic Average Shares
54,000
54,000
54,000
54,000
54,000
Diluted Average Shares
54,000
54,000
54,000
54,000
54,000
Total Expenses
1,519.8520
1,645.9740
1,884.9880
2,539.6740
2,084.7060
Net Income from Continuing & Discontinued Operation
-2,186.9980
-2,224.0480
-664.0760
-796.5070
-705.7630
Normalized Income
-1,249.7620
-1,280.8470
-654.7940
-747.8860
-692.4280
Interest Income
--
--
--
--
5.3920
Net Interest Income
-98.0210
-76.6530
-16.6380
-3.0370
5.3920
EBIT
-1,175.4660
-1,233.8840
-638.1560
-786.8260
-709.6010
EBITDA
-987.3750
-911.9790
-530.4310
-758.6600
-701.4290
Reconciled Cost of Revenue
268.6800
332.2890
963.0430
1,530.1790
1,193.3990
Reconciled Depreciation
188.0910
321.9050
107.7250
28.1660
8.1720
Net Income from Continuing Operation Net Minority Interest
-2,186.9980
-2,224.0480
-664.0760
-796.5070
-705.7630
Total Unusual Items Excluding Goodwill
-937.2360
-943.2010
-9.2820
-48.6210
-13.3350
Total Unusual Items
-937.2360
-943.2010
-9.2820
-48.6210
-13.3350
Normalized EBITDA
-50.1390
31.2220
-521.1490
-710.0390
-688.0940
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2020 - 10/27/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade